title: Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma.
abstract: Therapeutic vaccination against idiotype is a promising strategy for immunotherapy of B-cell malignancies. We have previously shown that CDR3-based DNA immunization can induce immune response against lymphoma and explored this strategy to provide protection in a murine B-cell lymphoma model. Here we performed vaccination employing as immunogen a naked DNA fusion product. The DNA vaccine was generated following fusion of a sequence derived from tetanus toxin fragment C to the V(H)CDR3(109-116) epitope. Induction of tumor-specific immunity as well as ability to inhibit growth of the aggressive 38C13 lymphoma and to prolong survival of vaccinated mice has been tested. We determined that DNA fusion vaccine induced immune response, elicited a strong protective antitumor immunity, and ensured almost complete long-term tumor-free survival of vaccinated mice. Our results show that CDR3-based DNA fusion vaccines hold promise for vaccination against lymphoma.
authors.affiliation: Institute of Neurobiology and Molecular Medicine, Department of Medicine, National Research Council (CNR), Via Fosso del Cavaliere 100, 00133 Rome, Italy.
authors.forename: Sandra
authors.initials: S
authors.lastname: Iurescia
authors.forename: Daniela
authors.initials: D
authors.lastname: Fioretti
authors.forename: Pasquale
authors.initials: P
authors.lastname: Pierimarchi
authors.forename: Emanuela
authors.initials: E
authors.lastname: Signori
authors.forename: Manuela
authors.initials: M
authors.lastname: Zonfrillo
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Tonon
authors.forename: Vito M
authors.initials: VM
authors.lastname: Fazio
authors.forename: Monica
authors.initials: M
authors.lastname: Rinaldi
mesh_terms: D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D016009:Chi-Square Distribution; D022801:Complementarity Determining Regions / Q000235:genetics / Q000276:immunology*; D018274:Electroporation; D005434:Flow Cytometry; D007371:Interferon-gamma / Q000378:metabolism; D053208:Kaplan-Meier Estimate; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology*; D013744:Tetanus Toxin / Q000235:genetics / Q000276:immunology*; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D022801:Complementarity Determining Regions; D010446:Peptide Fragments; D013744:Tetanus Toxin; D019444:Vaccines, DNA; C040635:tetanus toxin fragment C; D007371:Interferon-gamma
references.citation: Blood. 2002 Mar 1;99(5):1517-26
references.pmid: 11861263
references.citation: Blood. 1997 May 1;89(9):3129-35
references.pmid: 9129015
references.citation: Biochem Biophys Res Commun. 2008 May 30;370(2):279-84
references.pmid: 18364239
references.citation: Int Immunol. 2007 Nov;19(11):1291-301
references.pmid: 17906339
references.citation: J Immunol. 2007 Oct 1;179(7):4741-53
references.pmid: 17878373
references.citation: Adv Cancer Res. 2006;95:203-47
references.pmid: 16860659
references.citation: Nat Biotechnol. 1999 Mar;17(3):253-8
references.pmid: 10096292
references.citation: Nat Med. 1996 Jan;2(1):52-8
references.pmid: 8564842
references.citation: Nat Rev Genet. 2008 Oct;9(10):776-88
references.pmid: 18781156
references.citation: Cancer Detect Prev. 2001;25(5):470-8
references.pmid: 11718453
references.citation: CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29
references.pmid: 14974761
references.citation: Nat Med. 1996 Sep;2(9):1038-41
references.pmid: 8782465
references.citation: Clin Cancer Res. 2004 Dec 15;10(24):8309-17
references.pmid: 15623607
references.citation: Cancer Res. 2001 Feb 15;61(4):1555-62
references.pmid: 11245465
references.citation: J Immunol. 2001 Aug 1;167(3):1558-65
references.pmid: 11466377
references.citation: J Immunol. 1987 Oct 15;139(8):2825-33
references.pmid: 3498771
references.citation: Eur J Immunol. 1989 Dec;19(12):2237-42
references.pmid: 2481588
references.citation: Expert Rev Vaccines. 2006 Jun;5(3):381-94
references.pmid: 16827622
references.citation: Dev Comp Immunol. 2003 Jan;27(1):55-77
references.pmid: 12477501
references.citation: J Clin Invest. 2004 May;113(10):1498-510
references.pmid: 15146248
references.citation: Gene Ther. 2000 Apr;7(7):605-11
references.pmid: 10819576
references.citation: Nat Immunol. 2004 Nov;5(11):1143-8
references.pmid: 15475958
references.citation: Blood. 2003 Jun 15;101(12):4930-6
references.pmid: 12576325
references.citation: Trends Mol Med. 2001 Dec;7(12):566-72
references.pmid: 11733220
references.citation: Gene Ther. 2001 Aug;8(16):1264-70
references.pmid: 11509960
references.citation: DNA Cell Biol. 2004 Jun;23(6):395-402
references.pmid: 15231073
references.citation: Nat Rev Cancer. 2008 Feb;8(2):108-20
references.pmid: 18219306
references.citation: J Immunol. 1993 Sep 1;151(5):2871-6
references.pmid: 8360497
references.citation: J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):230-2
references.pmid: 18406604
references.citation: Immunogenetics. 1999 Nov;50(3-4):213-9
references.pmid: 10602881
references.citation: Blood Rev. 2009 May;23(3):137-42
references.pmid: 18951668
references.citation: Eur J Immunol. 1993 Feb;23(2):425-32
references.pmid: 7679644
references.citation: Blood. 2009 Jan 1;113(1):37-45
references.pmid: 18832136
references.citation: Cancer Immunol Immunother. 2008 Nov;57(11):1635-45
references.pmid: 18386000
references.citation: J Immunol. 1997 Aug 15;159(4):1885-92
references.pmid: 9257853
references.citation: Nat Med. 1998 Nov;4(11):1281-6
references.pmid: 9809552
references.citation: Biochem Biophys Res Commun. 2009 Jul 10;384(4):405-8
references.pmid: 19410556
references.citation: Vaccine. 2001 Feb 28;19(15-16):1931-9
references.pmid: 11228363
references.citation: Nature. 2003 Feb 20;421(6925):852-6
references.pmid: 12594515
references.citation: Curr Opin Oncol. 2005 Sep;17(5):432-40
references.pmid: 16093791
references.citation: N Engl J Med. 1992 Oct 22;327(17):1209-15
references.pmid: 1406793
references.citation: J Immunol. 1996 Dec 15;157(12):5503-11
references.pmid: 8955200
references.citation: Immunol Rev. 2004 Jun;199:156-80
references.pmid: 15233733
references.citation: Cancer Gene Ther. 2003 May;10(5):365-76
references.pmid: 12719706
references.citation: Eur J Immunol. 1977 Aug;7(8):574-9
references.pmid: 409606